MERTK and AXL are co-expressed with EGFR in NSCLC [58,69,80], and both receptors, but especially AXL, have been studied as causative drivers of secondary EGFR TKI resistance in mtEGFR-expressing NSCLCs [53,70,112,196]. This evidence concerns the gene MERTK and non-small cell lung carcinoma.